Company Insights

LUNG customer relationships

Explore interactive graphBrowse insights index
LUNG customer relationship map

Pulmonx (LUNG) — Payors, Partners and What Customer Relationships Mean for Revenue and Risk

Pulmonx manufactures the Zephyr Valve and accompanies that core hardware with the LungTraX cloud-enabled CT analysis platform; the company monetizes primarily through device sales to hospitals and recurring clinical services tied to LungTraX. Reimbursement support from major commercial payors and a strategic diagnostic partnership extend commercial access and lower adoption friction, while concentrated product exposure and single-site manufacturing present clear operational risk vectors for investors. For a concise view of third-party coverage and partnerships, see more at https://nullexposure.com/.

Why the customer list matters to investors: access, reimbursement, and sales motion

Pulmonx sells devices directly into hospitals and relies on third-party payors to reimburse procedures that use the Zephyr Valve. Positive coverage decisions from national and large regional insurers materially improve addressable market penetration because hospitals depend on payor policies to approve and bill for treatments. At the same time, Pulmonx generates the bulk of revenue from the Zephyr Valve hardware, leaving the stock sensitive to device adoption cadence and supply continuity.

If you want an operational risk and customer-concentration briefing tailored to institutional portfolios, visit https://nullexposure.com/ for a structured report.

Payors and partners listed in public records

  • Anthem — According to Pulmonx’s FY2024 10‑K, Anthem is listed among large commercial payors that have issued positive coverage policies for the Zephyr Valve, supporting reimbursement for eligible patients. (Source: FY2024 10‑K)

  • BCBS Michigan — Pulmonx’s FY2024 10‑K identifies BCBS Michigan as one of the Blue Cross Blue Shield plans that have issued positive coverage for the Zephyr Valve, which supports uptake in that state’s hospital networks. (Source: FY2024 10‑K)

  • Health Care Service Corporation (HCSC) — Pulmonx’s FY2024 10‑K lists HCSC among major payors providing positive coverage for the Zephyr Valve; earlier press coverage (RTTNews) also noted that HCSC issued a positive coverage policy last November for the device’s COPD indication. (Sources: FY2024 10‑K; RTTNews report referencing FY2021 coverage)

  • Aetna — The FY2024 10‑K names Aetna as a commercial payor that has issued a positive coverage policy for the Zephyr Valve, strengthening commercial access for Pulmonx procedures billed through Aetna plans. (Source: FY2024 10‑K)

  • Humana — Pulmonx’s FY2024 10‑K specifically calls out Humana among commercial payors with positive coverage, a helpful credential for national penetration given Humana’s managed care footprint. (Source: FY2024 10‑K)

  • Highmark — The FY2024 10‑K includes Highmark in the list of Blue plans that have issued positive coverage policies for the Zephyr Valve, supporting institutional adoption in Highmark-covered regions. (Source: FY2024 10‑K)

  • Jaeger™ Medical — A March 2026 news release reported a strategic partnership in which Jaeger Medical will integrate Pulmonx’s advanced data qualification functionality into SentrySuite™, Jaeger’s respiratory diagnostics software platform, extending Pulmonx’s clinical workflow presence beyond hardware sales into diagnostic software interoperability. (Source: Yahoo Finance press report, March 10, 2026)

What these relationships imply for Pulmonx’s operating model

Pulmonx’s public disclosures and news coverage reveal an operating profile with specific strengths and risks:

  • Direct-sales, hospital-focused contracting posture. The company markets and sells directly in the U.S. through its own sales organization, and hospitals are the counterparty for device purchases; those hospitals in turn bill payors for procedures. This structure accelerates margin capture on device sales but means sales cycles and purchasing decisions are institution-driven.

  • Reimbursement risk mitigated by major payor coverage. The presence of Anthem, Aetna, Humana, HCSC, BCBS Michigan and Highmark on the coverage list is a commercial enabler that reduces one of the key adoption barriers for capital and procedural devices.

  • Product concentration with a hardware-first revenue profile. Pulmonx reports that most revenue is generated from Zephyr Valves and delivery catheters; hardware sales dominate current economics while LungTraX represents an adjacent software revenue stream.

  • Operational concentration and criticality. Pulmonx performs substantially all manufacturing and R&D at a single Redwood City site and reports that 96% of revenue derives from markets where it sells directly—this single-site manufacturing posture creates a material operational dependency that elevates supply continuity risk.

  • Customer concentration is low at the account level but material by product. No single customer accounted for more than 10% of revenue in 2023–2024, which reduces counterparty concentration risk, but the company’s revenue is tightly coupled to one core product and to reimbursement acceptance.

  • Global market access with meaningful international revenue. International sales represented roughly one‑third of revenue in 2023–2024 and Pulmonx lists an established footprint across Europe, Asia Pacific and select other markets; international diversification is present but still dependent on continued regulatory and reimbursement access.

If you want a modeled exposure analysis and supply‑chain stress test against these constraints, request a customized briefing at https://nullexposure.com/.

Risk profile, timing and near-term monitoring priorities

  • Key operational risk: Single-location manufacturing and lack of redundant facilities concentrates execution risk; supply disruption would have immediate revenue impact given hardware-dominant sales.

  • Commercial risk: Continued expansion of payor coverage is the principal lever for adoption velocity; watch for additional national carriers and updates to payer medical necessity criteria.

  • Execution upside: Jaeger integration expands Pulmonx’s footprint within respiratory diagnostic workflows and can accelerate identification of eligible patients for Zephyr Valve treatment, translating diagnostic-to-procedure conversion if deployed at scale.

  • Maturity of relationships: Coverage by several large payors and international availability demonstrate commercial traction; relationships are active and commercialized rather than exploratory partnerships.

Bottom line: investment posture and tactical next steps

Pulmonx combines strong reimbursement credentials from major payors with a focused, hardware-driven revenue model and nascent software adjacency. The company’s commercial reach is broadening through diagnostic partnerships like Jaeger, but investors must weigh that progress against concentrated manufacturing risk and revenue dependence on a single device family.

Actionable items for portfolio managers and operators:

  • Monitor new payor coverage decisions and any changes to clinical eligibility criteria for the Zephyr Valve.
  • Track manufacturing redundancy plans and inventory metrics reported in upcoming filings.
  • Watch adoption metrics tied to Jaeger and LungTraX integrations for evidence of software-driven patient identification lifting device volumes.

To commission a deep-dive on Pulmonx’s customer exposure and operational contingencies, or to obtain a tailored risk brief, start here: https://nullexposure.com/.